NT-PROBNP as a screening tool for low-risk patent ductus arteriousus : a follow-up validation study
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
The purpose of the study is to test whether NT-proBNP serves as a screening tool for low-risk patent ductus arteriosus and safely avoids routine early echocardiography. This is a prospective observational study in preterm infants ≤32 weeks of gestational age. Infants with ≥5100 pg/ml (positive screening) at 48-72 hours of life received comprehensive echocardiography and were treated according to shunt severity. Infants with NT-proBNP below 5100 pg/ml (negative screening) were managed expectantly. The main outcome was need for ductus treatment within the first 7 days of life. One hundred twenty-five infants were included; 82 had a negative NT-proBNP screening and 43 had a positive NT-proBNP screening. No infant (0%) with a negative screening was treated for ductus while 26 (60.4%) with a positive screening were treated (p < 0.001). NT-proBNP avoided a 65.6% of routine echocardiograms. NT-proBNP had an excellent performance to predict PDA treatment (AUC = 0.967).Conclusion: NT-proBNP at 48-72 hours of life has an excellent performance to detect low risk and avoids unnecessary echocardiograms. This may contribute to optimize PDA management in terms of resource utilization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:182 |
|---|---|
| Enthalten in: |
European journal of pediatrics - 182(2023), 12 vom: 31. Dez., Seite 5465-5471 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
López-Blanco, Gloria [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 25.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00431-023-05213-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362694826 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362694826 | ||
| 003 | DE-627 | ||
| 005 | 20231227140904.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00431-023-05213-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1238.xml |
| 035 | |a (DE-627)NLM362694826 | ||
| 035 | |a (NLM)37773295 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a López-Blanco, Gloria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NT-PROBNP as a screening tool for low-risk patent ductus arteriousus |b a follow-up validation study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 25.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a The purpose of the study is to test whether NT-proBNP serves as a screening tool for low-risk patent ductus arteriosus and safely avoids routine early echocardiography. This is a prospective observational study in preterm infants ≤32 weeks of gestational age. Infants with ≥5100 pg/ml (positive screening) at 48-72 hours of life received comprehensive echocardiography and were treated according to shunt severity. Infants with NT-proBNP below 5100 pg/ml (negative screening) were managed expectantly. The main outcome was need for ductus treatment within the first 7 days of life. One hundred twenty-five infants were included; 82 had a negative NT-proBNP screening and 43 had a positive NT-proBNP screening. No infant (0%) with a negative screening was treated for ductus while 26 (60.4%) with a positive screening were treated (p < 0.001). NT-proBNP avoided a 65.6% of routine echocardiograms. NT-proBNP had an excellent performance to predict PDA treatment (AUC = 0.967).Conclusion: NT-proBNP at 48-72 hours of life has an excellent performance to detect low risk and avoids unnecessary echocardiograms. This may contribute to optimize PDA management in terms of resource utilization | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Echocardiography | |
| 650 | 4 | |a Natriuretic peptides | |
| 650 | 4 | |a Patent ductus arteriosus | |
| 650 | 4 | |a Preterm infant | |
| 650 | 4 | |a Screening | |
| 650 | 7 | |a pro-brain natriuretic peptide (1-76) |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Natriuretic Peptide, Brain |2 NLM | |
| 650 | 7 | |a 114471-18-0 |2 NLM | |
| 700 | 1 | |a Oulego-Erroz, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Pou-Blázquez, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Medina-Guerrero, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Blanco, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso-Quintela, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Muñuzuri, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Couce-Pico, Mari Luz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pediatrics |d 1978 |g 182(2023), 12 vom: 31. Dez., Seite 5465-5471 |w (DE-627)NLM000029718 |x 0340-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:182 |g year:2023 |g number:12 |g day:31 |g month:12 |g pages:5465-5471 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00431-023-05213-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 182 |j 2023 |e 12 |b 31 |c 12 |h 5465-5471 | ||